Epclusa 200 mg/1
Velpatasvir and Sofosbuvir · PELLET · Gilead Sciences, Inc.
Epclusa is an oral medication used to treat hepatitis C virus infection and contains two active ingredients that work together to stop the virus from replicating. It belongs to a class of drugs called nucleotide analog NS5B polymerase inhibitors, which target a specific enzyme the hepatitis C virus needs to survive.
Key Facts
- Brand Name
- Epclusa
- Generic Name
- Velpatasvir and Sofosbuvir
- NDC Code (Product)
61958-2204- Manufacturer
- Gilead Sciences, Inc.
- Strength
- 200 mg/1
- Dosage Form
- PELLET
- Route
- ORAL
- Marketing Status
- Application #
- NDA214187
- Drug Class
- Hepatitis C Virus NS5A Inhibitor [EPC]; Hepatitis C Virus Nucleotide Analog NS5B Polymerase Inhibitor [EPC]
- Marketing Start
- 06/10/2021
Recall History
No Recall HistoryFrequently Asked Questions
What is Epclusa used for?
Epclusa is an oral medication used to treat hepatitis C virus infection and contains two active ingredients that work together to stop the virus from replicating. It belongs to a class of drugs called nucleotide analog NS5B polymerase inhibitors, which target a specific enzyme the hepatitis C virus needs to survive.
Is Epclusa a controlled substance?
Epclusa is not classified as a controlled substance by the DEA.
What is the generic name for Epclusa?
The generic name for Epclusa is Velpatasvir and Sofosbuvir. There are 1 other brand versions of Velpatasvir and Sofosbuvir.
What is the NDC code for Epclusa 200 mg/1?
The NDC (National Drug Code) for Epclusa 200 mg/1 is 61958-2204, listed by Gilead Sciences, Inc..